Product image of Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide) supplied by GNH India

Mydrane

Active Ingredient:
Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide
Origin:
EU

Mydrane (Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide)

Lidocaine Hydrochloride, the active ingredient in Mydrane, is a combination ophthalmic agent presented as an intracameral solution for intraocular use. It provides rapid local anesthesia and facilitates pupil dilation during ophthalmic surgery.\n\nGNH India supplies Mydrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Laboratoires Thea

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Mydrane is used in ophthalmic procedures that require both anesthesia and pupil dilation.\n\nCataract surgery: provides effective pupil dilation and intraocular anesthesia to enable safe lens removal.\nIntraocular surgery (e.g., vitrectomy): facilitates mydriasis and analgesia for better surgical access.\nOther ophthalmic procedures: supports surgical exposure by dilating the pupil and delivering local anesthesia.

How It Works

  • Mydrane combines three agents that act on distinct ocular targets. Lidocaine blocks voltage‑gated sodium channels in corneal and intraocular nerves, producing rapid local anesthesia. Phenylephrine stimulates alpha‑1 adrenergic receptors on the iris dilator muscle, causing contraction and pupil dilation. Tropicamide antagonizes muscarinic receptors in the iris sphincter and ciliary body, leading to cycloplegia and additional mydriasis. The synergistic action yields prompt anesthesia and sustained pupil dilation for intraocular surgery.

Side Effects

  • Mydrane may cause a range of ocular and systemic reactions.\n\nCommon Side Effects:\n- Ocular discomfort or burning sensation\n- Transient increase in intra‑ocular pressure\n- Mild conjunctival hyperemia\n- Temporary blurred vision\n- Mild corneal edema\n- Light‑headedness or mild headache\n\nSerious or Rare Side Effects:\n- Severe allergic reaction (anaphylaxis)\n- Persistent mydriasis lasting >24 hours\n- Sustained intra‑ocular pressure elevation\n- Corneal ulceration or keratitis\n- Endophthalmitis\n- Retinal toxicity

Precautions & Warnings

  • Before using Mydrane, clinicians should consider several safety measures.\n\nPatient assessment: evaluate ocular health and allergy history.\nContraindications: avoid in patients with known hypersensitivity to lidocaine, phenylephrine, or tropicamide.\nIntra‑ocular pressure monitoring: check IOP before and after administration.\nCardiovascular caution: phenylephrine may raise systemic blood pressure; monitor hypertensive patients.\nPregnancy and lactation: limited data; use only if benefit outweighs risk.\nStore at ambient temperature: keep in original container, protect from light and moisture.

Avoid Interactions

  • Mydrane can interact with other medications that affect ocular or systemic physiology.\n\nMajor Interactions (Avoid):\n- Systemic alpha‑agonists (e.g., phenylephrine nasal spray) may cause additive hypertensive effects.\n- Monoamine oxidase inhibitors can potentiate phenylephrine‑induced blood pressure rise.\n- Concurrent use of other local anesthetics may increase risk of toxicity.\n\nModerate Interactions (Monitor Closely):\n- Topical non‑steroidal anti‑inflammatory drugs may delay corneal healing.\n- Systemic antihypertensives may blunt phenylephrine‑mediated pupil dilation.

Frequently Asked Questions

Mydrane is an intracameral ophthalmic solution used to provide local anesthesia and to dilate the pupil during intraocular procedures such as cataract extraction, vitrectomy, and other eye surgeries that require a clear surgical field.

Lidocaine blocks sodium channels in ocular nerves, producing rapid anesthesia. Phenylephrine activates alpha‑1 receptors on the iris dilator muscle, causing contraction and pupil enlargement. Tropicamide blocks muscarinic receptors in the iris sphincter and ciliary body, leading to cycloplegia and additional mydriasis. Together they deliver both analgesia and sustained dilation.

The dose of Mydrane is determined by the operating ophthalmologist based on the specific surgical procedure and patient characteristics. It is administered intracamerally in a single dose at the start of the operation.

Safety data for Mydrane in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the prescribing clinician.

To order Mydrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mydrane combines a local anesthetic (lidocaine) with two mydriatic agents (phenylephrine and tropicamide) in a single intracameral formulation, offering simultaneous anesthesia and pupil dilation. Alternative regimens often require separate administration of anesthetic and dilating drops, which can prolong preparation time and increase handling steps.

Mydrane should be stored at ambient temperature, below 25 °C, in its original sealed container. Protect the vial from direct light and moisture. Do not freeze or shake the solution before use.

Mydrane is administered by the surgeon directly into the anterior chamber of the eye (intracameral injection) at the beginning of the procedure. The injection is performed under sterile conditions using a calibrated syringe.

Serious risks include severe allergic reactions such as anaphylaxis, persistent mydriasis lasting more than 24 hours, sustained elevation of intra‑ocular pressure, corneal ulceration, endophthalmitis, and retinal toxicity. Prompt recognition and appropriate management are essential.

Mydrane is contraindicated in patients with known hypersensitivity to lidocaine, phenylephrine, tropicamide, or any component of the formulation. Caution is advised in patients with uncontrolled hypertension, severe cardiovascular disease, or active ocular infections.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lidocaine Hydrochloride Monohydrate, Phenylephrine Hydrochloride, Tropicamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT